GlaxoSmithKline, Emergent BioSolutions test Ebola vaccines
Posted by Leanne Kodsman on
According to FierceBiotech's March 18 article, GlaxoSmithKline (GSK) is testing out an Ebola vaccine in Africa. It is interested to find out if an immune reaction strong enough to overcome Ebola will occur.
If no strong immune response occurs, GSK will test Emergent BioSolutions' Ebola shot as a booster to their own vaccination. The two companies have partnered in this endeavor in Phase I trials at the University of Oxford.
According to FierceBiotech's March 18 article, GlaxoSmithKline (GSK) is testing out an Ebola vaccine in Africa. It is interested to find out if an immune reaction strong enough to overcome Ebola will occur.
If no strong immune response occurs, GSK will test Emergent BioSolutions' Ebola shot as a booster to their own vaccination. The two companies have partnered in this endeavor in Phase I trials at the University of Oxford.
Emergent, based in Maryland, announced that through partnerships with several different companies it was able to create an Ebola candidate called a modified vaccinia Ankara Ebola Zaire vaccine, or MVA EBOZ.
Emergent's candidate was produced using a scalable process which means it could be mass produced to meet demands for large numbers of doses.
Only Merck and NewLink are currently testing their candidates in Africa.